[A21-45] Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97

Last updated 20.05.2021

Project no.:
A21-45

Commission:
Commission awarded on 07.04.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy

Result of dossier assessment:

unchanged after addendum:

Patients with Child-Pugh A or no liver cirrhosis

  • with viral aetiology of HCC: indication of major added benefit,
  • with non-viral aetiology of HCC: hint of considerable added benefit.

Patients with Child-Pugh B: added benefit not proven.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021-05-20: A G-BA decision was published

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form